Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Monopar Therapeutics Director's Dealing 2018

Sep 27, 2018

32883_dirs_2018-09-27_86800b4e-aa4f-4046-9df3-e9d00c027d9c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-08-28

Reporting Person: Tsuchimoto Kim R (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-08-28 Stock options $6 A 41100 Acquired 2028-08-27 Common stock (41100) Direct

Footnotes

F1: Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.